Focus: Leo Pharma is a Danish-based specialty pharmaceutical company focused on small-molecule therapeutics in immunology and endocrinology, with a portfolio anchored by dermatology and anticoagulation assets.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Leo Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Blockbuster IL-13 antagonist driving 68% of company revenue with multi-indication expansion underway.
Help build intelligence for Leo Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Leo Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Peak-cycle combination therapy with 7+ years of exclusivity remaining; foam formulation in Phase 4.
Specialty dermatology asset facing patent cliff in 2029; represents patent cliff exposure.
Anticoagulation asset with Phase 2/3 and Phase 4 trials ongoing; diversifies away from dermatology.
JAK inhibitor in launch phase targeting eczema/dermatitis with 10-year exclusivity window.
3 discontinued, 7 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo